Item 8.01 Other Events.
On July 26, 2012, Cytokinetics, Inc. issued a press release announcing that the
company and Amgen have reviewed data arising from a recently completed Phase I
clinical trial designed to assess the safety, tolerability and pharmacokinetics
of modified release oral formulations of omecamtiv mecarbil in healthy
volunteers. This clinical trial was conducted by Amgen in collaboration with
Cytokinetics. Based on the review of these data, the companies have selected
oral formulations of omecamtiv mecarbil from this Phase I trial that warrant
further evaluation in patients with heart failure. Cytokinetics and Amgen are
discussing plans for the initiation of a Phase II clinical trial of these oral
formulations. Amgen holds an exclusive worldwide (excluding Japan) license to
omecamtiv mecarbil and related compounds, subject to specified development and
commercialization participation of Cytokinetics.
A copy of the press release is filed as Exhibit 99.1 to this Current Report on
Form 8-K, and is incorporated herein by reference.
Top of the Form
Add
CYTK to Portfolio
Set Alert
Email to a
Friend